GSK Committed To Phase II COX-2 Inhibitor Regardless Of FDA Cmte. Outcome
This article was originally published in Pharmaceutical Approvals Monthly
You may also be interested in...
GSK COX-2 Data Show No Short-Term Cardiovascular Risk, Company Says
GSK COX-2 agent shows no short-term cardiovascular risk, firm reports. Phase II agent 406381 has similar safety profile to Celebrex but offers an "incremental" efficacy benefit over Pfizer’s drug, GSK says. NDA is tentatively planned for late 2006, but timing may depend on FDA advisory committee meeting on COX-2 safety
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011
September 2010 Approvals
Product